

Personal Information



Ekaphop Sirachainan

Address: Ramathibodi hospital

Country: Thailand

Curriculum Vitae

EDUCATION

1981-1984 St. Gabriel's college, Bangkok, Thailand
1984-1990 Faculty of Medicine, Ramathibodi hospital, Mahidol University, Bangkok, Thailand; M.D.

PAST EXPERIENCE

General practitioner, Adisorn military hospital, Saraburi, Thailand
1992-1993 Internist, Anantamahidol military hospital, Lopburi, Thailand

POSTDOCTORAL TRAINING

1993-1996 Internal Medicine Residency, Ramathibodi hospital, Mahidol University, Bangkok, Thailand
1996-1999 Medical Oncology Fellowship, Ramathibodi hospital, Mahidol University, Bangkok, Thailand
1999-2002 Postdoctoral research fellow, Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, U.S.A.

ACADEMIC APPOINTMENTS

Assistant professor, Head of Oncology unit, Department of Medicine, Faculty of Medicine, Ramathibodi hospital, Mahidol University

CERTIFICATION AND LICENSURE

The Medical Council of Thailand License
Thai Board of Internal Medicine Certification
Thai Board of Medical Oncology Certification
Certification of Postdoctoral research fellowship, Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETY

Ramathibodi comprehensive cancer center committee
Royal college of Physician (Thailand)
Thai Society of Clinical Oncology (TSCO)
Vice President (2010-present)
American Society of Clinical Oncology (ASCO)
Asia Scientific Committee of ESMO Asia CME Partner Center: Colorectal Cancer Program
The Network of Colorectal Cancer Multi-Disciplinary Teams in the Asia Pacific Region
(NECTAR) Council

BIBLIOGRAPHY

Publications

Original articles

1. **Sirachainan E**, Kalemkerian GP. *Unusual presentations of lung cancer: case 2. Adrenal insufficiency as the initial manifestation of non-small-cell lung cancer.* J Clin Oncol. 2002 Dec 1; 20(23):4598-600.
2. **Sirachainan E**, Sumboonnanonda K, Dangprasert S, Panvichian R, Sirisinha T, Dhanachai M, et al. *Preoperative chemoradiotherapy in locally advanced rectal cancer: Ramathibodi experience.* J Med Assoc Thai 2005 Feb; 88(2):162-7.
3. **Sirachainan E**, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, Sukasem C. *CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients.* Pharmacogenomics and Personalized Medicine 2012; 5:149-153
4. **Sirachainan E**, Reungwetwattana T, Wisetpanit Y, Panvichian R, Sirisinha T, et al. *Pharmacogenetic Study of 5-Fluorouracil-Related Severe Toxicity in Thai Cancer Patients: A Novel SNP Detection.* J Pharmacogenom Pharmacoproteomics 2012; 3(5) doi:10.4172/2153-0645.1000112.
5. Ratanatharathorn V, Jirajarus M, **Sirachainan E**, Sirilertrakul S, Euaree A, Supatchaipisit P. *Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): a preliminary study.* J Med Assoc Thai. 1998 Oct; 81(10):763-71.
6. Ratanatharathorn V, Lorvidhaya V, Kraipiboon P, **Sirachainan E**, Maoleekoonpairoj S, Phromratanapongse P, Cheirsilpa A, Tangkaratt S, Srimuninnimit V, Pattranutaporn P, Lertsanguansinchai P. *Phase II study of concurrent chemoradiotherapy for inoperable (bulky) stage III (A/B) non-small cell lung cancer (NSCLC): a preliminary report.* J Med Assoc Thai. 2000 Jan; 83(1):85-92.
7. Ratanatharathorn V, **Sirachainan E**, Jirajarus M. *Effects of paclitaxel and carboplatin on quality of life and survival in patients with advanced non-small-cell lung cancer.* J Med Assoc Thai. 2000 Sep; 83(9):1059-67.
8. Ratanatharathorn V, **Sirachainan E**, Jirajarus M, Sirilertrakul S. *Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.* J Med Assoc Thai. 2000 Oct; 83(10):1187-95.
9. Sirisinha T, Ratanatharathorn V, Jirajarus M, Sirilertrakul S, Silpakit C, **Sirachainan E**, Tanvetyanon T. *The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire: Translation and Reliability Study of The Thai Version.* J Med Assoc Thai. 2002 Nov; 85(11):1210-19.
10. Tanasrijun K, **Sirachainan E**. *Hypercalcemia as an initial presentation of Breast cancer: Report of two cases.* Intern Med J Thai. 2005; 21: 136-144.
11. Silpakit C, Sirilertrakul S, Jirajarus M, Sirisinha T, **Sirachainan E**, Ratanatharathorn V. *The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Validation study of the Thai version.* Quality of life research. 2006; 15:

- 167-172.
12. Dhanachai M, Kraiphibul P, Dangprasert S, Puataweepong P, Narkwong L, Laothamatas J, Kulapraditharom B, **Sirachainan E**, Yongvithisatid P. *Fractionated stereotactic radiotherapy in residual or recurrent nasopharyngeal carcinoma*. *Acta Oncol* 2007; 46(6):828-833.
 13. Phongkitkarun S, Phaisanphrukun C, Jatchavala J, **Sirachainan E**. *Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate*. *World J Gastroenterol* 2008; 14(6): 892-898.
 14. Larbchareonsub N, Leopairat J, **Sirachainan E**, Narkwong L, Bhongmakapat T, Rasmeepaisan K, Janvilisri T. *Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy*. *Hum Pathol* 2008; 39(6): 837-845.
 15. Larbcharoensub N, Sornmayura P, **Sirachainan E**, Wilasrusmee C, Wanmoung H, Janvilisri T. *Prognostic value of ABCG2 in moderately and poorly differentiated intrahepatic cholangiocarcinoma*. *Histopathology* 2011, 59 (2): 235-24.
 16. Sukasem C, **Sirachainan E**, Chamnanphon M, Pechatanan K, Sirisinha T, Ativitavas T, Panvichian R, Ratanatharathorn V, Trachu N, Chantratita W. *Impact of CYP2D6 Polymorphisms on Tamoxifen Responses of Women with Breast Cancer: A Microarray-based Study in Thailand*. *Asian Pacific J Cancer Prev* 2012, 13 (9): 4549-4553.
 17. Butthongkomvong K, **Sirachainan E**, Jhankumpha S, Kumdang S, Sukhontharot O.-U. *Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand*. *Asian Pacific Journal of Cancer Prevention* 2013, 14 (6): 3565–3568.
 18. Sensorn I, **Sirachainan E**, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, Sukasem C, Pinthong D. *Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen*. *Pharmacogenomics and Personalized Medicine* 2013, 6 (1): 93–98.
 19. Soon SS, Lim HY, Lopes G, Ahn J, Hu M, Ibrahim HM, Jha A, Ko BS, Lee PW, MacDonell D, **Sirachainan E**, Wee HL. *Roles of cancer registries in enhancing oncology drug access in the asia-pacific region*. *Asian Pacific Journal of Cancer Prevention* 2013, 14 (4): 2159–2165.
 20. Soon SS, Lopes G, Lim HY, Wong-Rieger D, Bahri S, Hickinbotham L, Jha A, Ko BS, MacDonell D, Pwu J, Shih R, **Sirachainan E**, Suh DC, Wale J, Zhang X, Wee HL. *A call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region*. *Orphanet Journal of Rare Diseases* 2014, 9: 137
 21. Larbcharoensub N, Kanoksil W, Cheewaruangroj W, Wiratkapun C, Sitathanee C, **Sirachainan E**. *Esthesioneuroblastoma metastasis to the breast: A case report and review of the literature*. *Oncology letters* 10/2014; 8(4): 1505-1508
 22. Atasilp C, Chansriwong P, **Sirachainan E**, Reungwetwattana T, Chamnanphon M, Puangpetch A, Wongwaisayawan S, Sukasem C. *Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients*. *Drug Metab Pharmacokinet* 2016 Feb;31(1):90-4. doi: 10.1016/j.dmpk.2015.12.004. Epub 2015 Dec 31
 23. Tulalamba W, Larbcharoensub N, **Sirachainan E**, Tantiwetrueangdet A, Janvilisri T. *Transcriptome meta-analysis reveals dysregulated pathways in nasopharyngeal carcinoma*. *Tumor Biol* 2015 Aug;36(8):5931-42. doi: 10.1007/s13277-015-3268-7. Epub 2015 Feb 28.
 24. Sukasem C, Atasilp C, Chansriwong P, Chamnanphon M, Puangpetch A, **Sirachainan E**. *Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal Cancers*. *Journal of Clinical Laboratory Analysis* 30: 84–89 (2016)
 25. Sensorn I, Sukasem C, **Sirachainan E**, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, Pinthong D, Wongwaisayawan S. *ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen*. *OncoTargets and Therapy* 2016;9 2121–2129

Book sections

1. **Sirachainan E.** *Signal Transduction*, In Ratanatharathorn V, editor. Textbook of Medical Oncology Bangkok: Holistic Publishing; 1998, p. 27-42.
2. **Sirachainan E**, Vilailuck S. *Granulocyte colony stimulating factor therapy in solid tumor*. In: Vilailuck S, editor. Ovarian cancer. Bangkok: Holistic publishing; 2005, p. 170-80.
3. **Sirachainan E.** *Adjuvant Chemotherapy for Colorectal Cancer*. In: Kongdan Y, editor. Optimal Quality in Surgical care. Bangkok: Krungthep Vejjasarn publishing; 2005, p. 89-92.
4. **Sirachainan E.** *Spinal cord compression*. In: Limpijarnkit T, editor. Emergency in Medicine. Bangkok: Srangsoe; 2006, p. 485-88
5. **Sirachainan E.** *Carcinogenesis*. In: Jitchareon A, editor. The Celebrations on the Auspicious Occasion of His Majesty the King's 80th Birthday anniversary meeting. Bangkok: Beyond Enterprise; 2007, p. 149-52
6. **Sirachainan E.** *Pharmacogenomics in cancer*. In: Jitchareon A, editor. The Celebrations on the Auspicious Occasion of His Majesty the King's 80th Birthday anniversary meeting. Bangkok: Beyond Enterprise; 2007, p. 184-87
7. **Sirachainan E.** *Hypercalcemia*. In: Sumethkul W, editors. State of the arts in emergency and critical care medicine. Bangkok: Offset creation; 2007. p. 265-68.
8. **Sirachainan E.** *Do we make progress in systemic treatment of pancreatic cancer?* In: Sirisinha T, editor. Optimal Management in Gastrointestinal oncology. Bangkok: Huanam printing; 2009, p. 91-98.
9. **Sirachainan E.** *Principles of medical oncology*. In: Lertsithichai P, editors. Surgical Oncology Interdisciplinary approach to common surgical cancers. Bangkok: Krungthep Wechasarn; 2009, p. 125-30.
10. **Sirachainan E.** *Multidisciplinary treatment of rectal cancer*. In: Suwanthanma V, editors. Update Management in Colorectal Disease 2012. Bangkok: Krungthep Wechasarn; 2012, p. 278-83.
11. **Sirachainan E.** *Where do we go from here in antiangiogenesis in colorectal cancer*. In: Dejthevaporn T, editor. Targeted therapy on the horizon. Bangkok: PCK design; 2013, p. 89-94

Oral presentation

1. **Sirachainan E**, Urban FA, Huges DP, MacGregor JN, Baskar D, Li SP and McDonagh KT. *Development of a real-time quantitative PCR assay for universal detection of recombinant Moloney murine leukemia proviral genome in transduced hematopoietic cells*. Twenty-sixth Annual meeting of the Thai Society of Hematology, January 17-19, 2003, Bangkok, Abstract# 15
2. **Sirachainan E**, Sumpunnanon K, Dangprasert S, Panvichian R, Sirisinha T, Dhanachai M, Piratvej W, Kraipiboon P, Chatchavala J, Ratanatharathorn V. *Preoperative chemoradiotherapy in locally advanced rectal cancer: Ramathibodi experience*. The 7th National Cancer Conference: Oncology II after 2000, November 12-14, 2003, Bangkok, Abstract # O-7
3. **Sirachainan E**, Euanorasetr C, Sirisinha T, Panvichian R, Kanjanapanjapol S, Ratanatharathorn V. *Phase II Study Oxaliplatin (OXALIP), 5-FU, Leucovorin (FOLFOX4) in The First-line Treatment of Metastatic Colorectal Cancer: A Preliminary Report*. The 8th National Cancer Conference, September 7-9, 2005, Bangkok, Abstract # O-5
4. **Sirachainan E**, Trachu N, Wisetpanit Y, Panvichian R, Ratanavila A, Chintrakarn C, Sirisinha T, Ativitavas T, Ratanatharathorn V. *Peripheral blood quantitative PCR analysis of EBV DNA in nasopharyngeal carcinoma*. The 5th Roche Asia Oncology Forum (RAOF), November 3-5, 2006, Hong Kong
5. **Sirachainan E**, Sitathanee C, Phongkitkarun S, Suwanthanma W, Larbcharoensub N, Trachu N, Lukrak S, Sumboonnanda K. *Preoperative concurrent CAPOX-radiotherapy in Thai*

- locally advanced rectal cancer patients.* Asian Oncology Summit 2013, March 22 – 24, 2013, Bangkok
6. Reungwetwattana T, Trachu N, Wisetpanit Y, **Sirachainan E.** *Molecular characterizations of Dihydropyrimidine dehydrogenase (DPD) deficiency in Thai patients affected by 5-FU.* The 6th Roche Asia Oncology Forum (RAOF), August 11-12, 2007, Malaysia
 7. Jaruhathai S, **Sirachainan E.**, Ativitavas T, Sirisinha T, Panvichian R, Ratanatharathorn V. *Cytochrome P450 2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients.* The 7th Roche Asia Oncology Forum (RAOF), November 7-8, 2008, Bangkok

Poster presentation

1. **Sirachainan E.**, Urban FA, Huges DP, MacGregor JN, Baskar D, Li SP and McDonagh KT. *Development of a real-time quantitative PCR assay for universal detection of recombinant Moloney murine leukemia proviral genome in transduced hematopoietic cells.* Tenth Annual Department of Internal Medicine Research Symposium, May 10-11, 2002, Towsley Center, University of Michigan, Abstract# 77.
2. **Sirachainan E.**, Trachu N, Wisetpanit Y, Panvichian R, Ratanavila A, Chintrakarn C, Sirisinha T, Ativitavas T, Ratanatharathorn V. *Peripheral blood quantitative PCR analysis of EBV DNA in nasopharyngeal carcinoma.* American Society of Clinical Oncology 42nd annual meeting, June 2-6, 2006, Atlanta, Abstract# 5557.
3. **Sirachainan E.**, Jirajarus M, Sirilertrakul S, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V. *The prevention of delayed admission for chemotherapy administration.* International Conference on Health Promotion and Quality in Health Services (IHQS), November 19-21, 2008, Bangkok, Abstract# IP-083, (3rd Poster Winner)
4. Ratanavila A, Panvichian R, Waeteekul S, **Sirachainan E.**, Kuhapraema T, Jirasiritham S, Leelaudomliti S, Ratanatharathorn V. *Analysis of genomic aberrations in human hepatocellular carcinoma using comparative genomic hybridization.* American Association for Cancer Research 94th Annual Meeting, July 11-14, 2003, Washington D.C., Abstract# 3238
5. Sirisinha T, Jirajarus M, **Sirachainan E.**, Panvichian R, Ratanatharathorn V. *Gefinitib treatment for locally advanced and metastatic NSCLC under expanded access program at Ramathibodi hospital.* The First Asia Pacific Lung Cancer Conference, August 25-27, 2004, Chiang Mai, Abstract# 21
6. Ratanavila A, Panvichian R, Vongvaisyavarn S, Leelaudomlipi S, Visetpanich U, Yingyong W, Tirapanich W, **Sirachainan E.** *Candidate tumor-suppressor gene loci on chromosome 22q13, D22S284 marker, associated with the metastasis potential of human breast cancer.* Association for Cancer Research 96th Annual Meeting, April 16-20, 2005, Anaheim/Orange county, Abstract# 1886
7. Chompoonuch S, **Sirachainan E.** *Olfactory neuroblastoma-Ramathibodi experience.* Asian Oncology Summit, April 8-10, 2011, Hong Kong, Abstract# P22
8. Autkittanon P, Reukumneuychok B, Limsuwanachot N, Ativitavas T, Sirisinha T, Panvichian R, Ratanatharathorn V, **Sirachainan E.** *KRAS genotypes in Thai patients with colorectal cancer.* Asian Oncology Summit, April 13-15, 2012, Singapore, Abstract#17
9. Trachu N, Chanchairungcharoen S, Ativitavas T, Sirisinha T, Panvichian R, Ratanatharathorn V, **Sirachainan E.** *Four dihydropyrimidine dehydrogenase genotypes (1627A>G, 967G>A, 1774C>T and IVS14+G>A) as a predictive factors for toxicity in Thai patients treated with single agent 5-FU or capecitabine in ramathibodi hospital.* Human Genome Meeting 2014, April 27-30, 2014, Geneva, Abstract# P208
10. Konmun J, Danwilai K, Ngamphaiboorn N, Sookprasert A, **Sirachainan E.**, Subongkot S. *A phase II randomized, double-blind placebo-controlled trial of an antiemetic, 6-gingerol in solid tumor patients receiving moderately to highly emetogenic adjuvant chemotherapy.* American Society of Clinical Oncology 50th annual meeting, May 30-June 3, 2014, Chicago, Abstract# 9647

Abstract

1. **Sirachainan E**, Ratanatharathorn V, Laohavanij S, et al. *Phase II Study Taxol and Carboplatin in Combination in the Treatment of Advanced Non-small-cell Lung Cancer (NSCLC)*. Ramathibodi Medical Journal 1997; 20 (suppl.): 22a
2. **Sirachainan E**, Ratanatharathorn V, Euaree A, et al. *Paclitaxel and Carboplatin in combination in the treatment of Advanced Non-small-cell Lung Cancer (NSCLC)*. Ramathibodi Medical Journal 1998; 21(suppl.): 27a
3. **Sirachainan E**: *Cancer vaccine*. Ramathibodi Medical Journal 2003 May; 26 (suppl.1): pp 165
4. **Sirachainan E**, Sitathanee C, Phongkitkarun S, Suwanthanma W, Larbcharoensub N, Trachu N, Lukrak S, Sumboonnanda K. *Correlation of APC, CYP3A4, and ESR2 expressions in locally advanced rectal cancer with the pathologic response of preoperative concurrent CAPOX/RT*. J Clin Oncol : 2014 (suppl; abstr e14610)
5. Laohavinij S, Maoleekoonpairroj S, Cheirsilpa A, Maneechavakajorn J, **Sirachainan E**, Arpornvirat W, K Jaisathaporn, V Ratanatharathorn. *Phase II Study of Paclitaxel and Carboplatin for Advanced Non-Small-Cell Lung Cancer (NSCLC)*. Proc. ASCO 1999; 18: 1981a.
6. Sirilertrakul S, Jirajarus M, Ratanatharathorn V, Hanucharenrkul S, **Sirachainan E**, Ninchai Kovit T. *The Reliability and Item-Total Correlation of the Functional Assessment of Cancer Therapy [Fact] Scale in Cancer Patients in Thai Version*. Proc Am Soc Clin Oncol 19: 2000 (abstr 2531)
7. Sirisinha T, Sirilertrakul S, Kraiphibul P, Dangprasert S, **Sirachainan E**, Ativitavas T, Ratanatharathorn V. *Phase II study of concurrent chemoradiation with gemcitabine (GEM) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary result*. J Clin Onco 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 15519
8. Dhanachai M, Kraiphibul P, Pochanugool L, Dangprasert S, Puataweepong P, Narkwong L, Laothamatas J, Kulpraditharom B, Theerapanchareon V, **Sirachainan E**, Yongvithisatid P, Assavaprathuangkul P. *Fractionated stereotactic radiotherapy in residual or recurrent nasopharyngeal carcinoma*. Ramathibodi Medical Journal 2006; 29(suppl 1): 55.
9. Silpakit C, Sirilertrakul S, Jirajarus M, Sirisinha T, **Sirachainan E**, Ratanatharathorn V. *The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Validation study of the Thai version*. Ramathibodi Medical Journal 2006; 29 (suppl 1):35.
10. Chansriwong P, Ratanatharathorn V, Panvichian R, **Sirachainan E**, Sirisinha T, Ativitavas T. *A retrospective study of high grade glioma in Ramathibodi hospital*. Ramathibodi Medical Journal 2006; 29 (suppl 1):149.
11. Nakhakes C, Ratanatharathorn V, Panvichian R, **Sirachainan E**, Sirisinha T, Ativitavas T. *Outcome of postoperative chemoradiation in completely resected gastric adenocarcinoma: Ramathibodi hospital experience year2000-2005*. Ramathibodi Medical Journal 2006; 29 (suppl 1):145.
12. Taengdaen S, Panvichian R, Ativitavas T, **Sirachainan E**, Sirisinha T, Ratanatharathorn V. *Ten years adult germ cell tumors in Ramathibodi hospital: a retrospective pathologic and clinical analysis during year 1995-2004*. Ramathibodi Medical Journal 2006; 29 (suppl 1):150.
13. Raunroadroong N, **Sirachainan E**. *Retrospective review of small cell lung cancer at Ramathibodi hospital*. Ramathibodi Medical Journal 2006; 29 (suppl 1):160.
14. Sanmanowong P, Putwatana P, Junda T, **Sirachainan E**. *Efficacy of glycerine payayor in prevention and relief of oral mucositis among patients with cancer receiving chemotherapy*. Ramathibodi Medical Journal 2006; 29 (suppl 1):8.
15. Reungwetwattana T, **Sirachainan E**, Trachu N, Wisetpanit Y, Mahasirimongkol S, Panvichian R, Sirisinha T, Ratanatharathorn V, Ativitavas T. *Dihydropyrimidine*

- dehydrogenase (DPD) single nucleotide polymorphisms (SNP) in Thai patients treated with 5-FU based regimens. J Clin Oncol 26: 2008 (May 20 suppl; abstr 14537)*
16. Pechatanan K, Jaruhathai S, Ativitavas T, Sirisinha T, Panvichian R, Ratanatharathorn V, **Sirachainan E**. *Cytochrome P450 2D6 polymorphisms of Thai patients with breast cancer and their outcomes of adjuvant tamoxifen. J Clin Oncol 29: 2011 (suppl; abstr e11037)*

Speaker

1. *Treatment of metastatic pancreatic cancer. World Congress on Gastrointestinal Cancer: Asian Perspectives, August 23, 2008, Bangkok.*
2. *Variation in RAS mutation patterns among diverse ethnicities. 3rd Asia-Pacific Gastroenterology Cancer Summit 2016, May 1, 2016, Bangkok.*

Principal investigator

1. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. *Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-37*
2. ELSIE: open, uncontrolled, multicenter, phase II Asian/Australian study of Erbitux™ (cetuximab) in combination with irinotecan in patients with metastatic colorectal adenocarcinoma expressing the epidermal growth factor receptor (EGFR) and having progressed on a defined irinotecan-based regimen as most recent treatment
3. A Phase III, International, Randomized, Double-Blind, Parallel-Group, Multi-Centre Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB – IV) Non-Small Cell Lung Cancer (NSCLC) after Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)
4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. *Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009 September 3, 2009; 361(10):947-57*